180 related articles for article (PubMed ID: 38767132)
1. Switching patterns of biological drugs in patients with psoriasis and psoriatic arthritis: insight from the VALORE database network.
Spini A; Pellegrini G; Ingrasciotta Y; L'Abbate L; Bellitto C; Carollo M; Leoni O; Zanforlini M; Ancona D; Stella P; Cavazzana A; Scapin A; Lopes S; Belleudi V; Ledda S; Carta P; Rossi P; Ejlli L; Sapigni E; Puccini A; Spila Alegiani S; Massari M; Guarneri C; Gisondi P; Trifirò G
Expert Opin Biol Ther; 2024 May; 24(5):399-409. PubMed ID: 38767132
[TBL] [Abstract][Full Text] [Related]
2. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
[TBL] [Abstract][Full Text] [Related]
3. Real-world use of biological drugs in patients with psoriasis/psoriatic arthritis: a retrospective, population-based study of years 2010-2014 from Southern Italy.
Marcianò I; Randazzo MP; Panagia P; Intelisano R; Sgroi C; Ientile V; Cannavò S; Guarneri C; Reitano P; Spina E; Trifirò G
G Ital Dermatol Venereol; 2020 Aug; 155(4):441-451. PubMed ID: 29582617
[TBL] [Abstract][Full Text] [Related]
4. Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database.
Pina Vegas L; Penso L; Claudepierre P; Sbidian E
JAMA Dermatol; 2022 May; 158(5):513-522. PubMed ID: 35319735
[TBL] [Abstract][Full Text] [Related]
5. Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey.
Potenza MC; Peris K; Berardesca E; Bianchi L; Richetta A; Bernardini N; De Simone C; Teoli M; Zangrilli A; D'epiro S; Orsini D; Narcisi A; Chimenti S; Costanzo A
Dermatol Ther; 2018 Jan; 31(1):. PubMed ID: 29215183
[TBL] [Abstract][Full Text] [Related]
6. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis.
Li X; Andersen KM; Chang HY; Curtis JR; Alexander GC
Ann Rheum Dis; 2020 Feb; 79(2):285-291. PubMed ID: 31672774
[TBL] [Abstract][Full Text] [Related]
7. Pharmaco-utilization of biologic drugs in patients affected by psoriasis, psoriatic arthritis and ankylosing spondylitis in an Italian real-world setting.
Zagni E; Colombo D; Fiocchi M; Perrone V; Sangiorgi D; Andretta M; De Sarro G; Nava E; Degli Esposti L
Expert Rev Pharmacoecon Outcomes Res; 2020 Oct; 20(5):491-497. PubMed ID: 32701033
[TBL] [Abstract][Full Text] [Related]
8. A single-centre, observational, retrospective, real-life study evaluating adalimumab biosimilar ABP 501 in the treatment of plaque-type psoriasis and psoriatic arthritis in originator-naïve patients and in patients undergoing non-medical switch from originator.
Giunta A; Zangrilli A; Bavetta M; Manfreda V; Pensa C; Bianchi L
Curr Med Res Opin; 2021 Jul; 37(7):1099-1102. PubMed ID: 34011212
[TBL] [Abstract][Full Text] [Related]
9. Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS).
Blauvelt A; Leonardi CL; Gaylis N; Jauch-Lembach J; Balfour A; Lemke L; Hachaichi S; Brueckmann I; Festini T; Wiland P
BioDrugs; 2021 Mar; 35(2):229-238. PubMed ID: 33651341
[TBL] [Abstract][Full Text] [Related]
10. Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University Psoriasis Registry.
Bayaraa B; Imafuku S
J Dermatol; 2019 May; 46(5):389-398. PubMed ID: 30861182
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis.
Ditto MC; Parisi S; Priora M; Sanna S; Peroni CL; Laganà A; D'Avolio A; Fusaro E
Sci Rep; 2020 Sep; 10(1):16178. PubMed ID: 32999362
[TBL] [Abstract][Full Text] [Related]
12. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis.
Acosta Felquer ML; LoGiudice L; Galimberti ML; Rosa J; Mazzuoccolo L; Soriano ER
Ann Rheum Dis; 2022 Jan; 81(1):74-79. PubMed ID: 34281904
[TBL] [Abstract][Full Text] [Related]
13. Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin-17 Inhibitors: A Nationwide Population-Based Study Using the French National Health Data System.
Penso L; Bergqvist C; Meyer A; Herlemont P; Weill A; Zureik M; Dray-Spira R; Sbidian E
Arthritis Rheumatol; 2022 Feb; 74(2):244-252. PubMed ID: 34279061
[TBL] [Abstract][Full Text] [Related]
14. An online survey among US patients with immune-mediated conditions: Attitudes about biosimilars.
Gibofsky A; Jacobson G; Franklin A; O'Hara-Levi S; Peyrin-Biroulet L; McGrath M; McCabe D
J Manag Care Spec Pharm; 2023 Apr; 29(4):343-349. PubMed ID: 36989450
[No Abstract] [Full Text] [Related]
15. Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study.
Scrivo R; Castellani C; Mancuso S; Sciarra G; Giardina F; Bevignani G; Ceccarelli F; Spinelli FR; Alessandri C; Di Franco M; Riccieri V; Priori R; Conti F
Clin Exp Rheumatol; 2023 Mar; 41(3):613-619. PubMed ID: 35916302
[TBL] [Abstract][Full Text] [Related]
16. Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project.
Trifirò G; Isgrò V; Ingrasciotta Y; Ientile V; L'Abbate L; Foti SS; Belleudi V; Poggi F; Fontana A; Moretti U; Lora R; Sabaini A; Senesi I; Sorrentino C; Puzo MR; Padula A; Fusco M; Giordana R; Solfrini V; Puccini A; Rossi P; Del Zotto S; Leoni O; Zanforlini M; Ancona D; Bavaro V; Garau D; Ledda S; Scondotto S; Allotta A; Tuccori M; Gini R; Bucaneve G; Franchini D; Cavazzana A; Biasi V; Spila Alegiani S; Massari M;
BioDrugs; 2021 Nov; 35(6):749-764. PubMed ID: 34637126
[TBL] [Abstract][Full Text] [Related]
17. Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP).
Tveit KS; Duvetorp A; Østergaard M; Skov L; Danielsen K; Iversen L; Seifert O
J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):340-354. PubMed ID: 30242921
[TBL] [Abstract][Full Text] [Related]
18. Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry.
Mease PJ; Karki C; Liu M; Li Y; Gershenson B; Feng H; Hur P; Greenberg JD
RMD Open; 2019; 5(1):e000880. PubMed ID: 31168408
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database.
Pauline O; Robert M; Bernardeau C; Hlavaty A; Fusaroli M; Roustit M; Cracowski JL; Khouri C
BioDrugs; 2023 Sep; 37(5):699-707. PubMed ID: 37278971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
